Should patient enrollment criteria for anti-VEGF phase III trials be reconsidered.
作者信息
Hanhart Joel, Jeon Sohee, Tuuminen Raimo
机构信息
Department of Ophthalmology, Shaare Zedek Medical Center, Jerusalem, Israel.
Hebrew University of Jerusalem, Jerusalem, Israel.
出版信息
J Diabetes. 2023 Oct;15(10):911-912. doi: 10.1111/1753-0407.13468. Epub 2023 Sep 20.
Abstract
摘要
相似文献
1
Should patient enrollment criteria for anti-VEGF phase III trials be reconsidered.
J Diabetes. 2023 Oct;15(10):911-912. doi: 10.1111/1753-0407.13468. Epub 2023 Sep 20.
2
Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Cochrane Database Syst Rev. 2020 Jul 7;7(7):CD009510. doi: 10.1002/14651858.CD009510.pub3.
3
Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD011599. doi: 10.1002/14651858.CD011599.pub2.
4
Topical Dorzolamide-Timolol With Intravitreous Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration.
JAMA Ophthalmol. 2016 Apr;134(4):437-43. doi: 10.1001/jamaophthalmol.2016.0045.
5
Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
Cochrane Database Syst Rev. 2014 May 1;2014(5):CD007325. doi: 10.1002/14651858.CD007325.pub3.
6
Anti-vascular endothelial growth factor for neovascular glaucoma.
Cochrane Database Syst Rev. 2013 Oct 2;10(10):CD007920. doi: 10.1002/14651858.CD007920.pub2.
7
Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Cochrane Database Syst Rev. 2013 Jan 31(1):CD009510. doi: 10.1002/14651858.CD009510.pub2.
8
Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
Cochrane Database Syst Rev. 2014 Nov 24;2014(11):CD008721. doi: 10.1002/14651858.CD008721.pub2.
9
Vascular endothelial growth factor and its inhibitors.
Drugs Today (Barc). 2003;39 Suppl C:81-93.
10
Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion.
Cochrane Database Syst Rev. 2010 Oct 6(10):CD007325. doi: 10.1002/14651858.CD007325.pub2.
本文引用的文献
1
A diabetes update.
J Diabetes. 2023 Jul;15(7):542-544. doi: 10.1111/1753-0407.13434. Epub 2023 Jun 13.
2
Systemic Adverse Events Among Patients With Diabetes Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
JAMA Ophthalmol. 2023 Jul 1;141(7):658-666. doi: 10.1001/jamaophthalmol.2023.2098.
3
Difficulty in Assessing the Systemic Adverse Effects of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy.
JAMA Ophthalmol. 2023 Jul 1;141(7):666-667. doi: 10.1001/jamaophthalmol.2023.2307.
4
A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.
Nephrol Dial Transplant. 2023 Jun 30;38(7):1666-1681. doi: 10.1093/ndt/gfac305.
5
Cardiovascular and Mortality Risk with Intravitreal Vascular Endothelial Growth Factor Inhibitors in Patients with Diabetic Retinopathy.
Ophthalmol Retina. 2022 Dec;6(12):1145-1153. doi: 10.1016/j.oret.2022.06.010. Epub 2022 Jun 28.
6
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24.
7
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24.
8
Association Between Mortality and Anti-Vascular Endothelial Growth Factor Treatment in Patients With Age-Related Macular Degeneration.
JAMA Ophthalmol. 2021 Nov 1;139(11):1246-1247. doi: 10.1001/jamaophthalmol.2021.4079.
9
Severity of Diabetic Retinopathy and the Risk of Future Cerebrovascular Disease, Cardiovascular Disease, and All-Cause Mortality.
Ophthalmology. 2021 Aug;128(8):1169-1179. doi: 10.1016/j.ophtha.2020.12.019. Epub 2020 Dec 25.
10
HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Ophthalmology. 2021 Jan;128(1):89-99. doi: 10.1016/j.ophtha.2020.06.028. Epub 2020 Jun 20.
Zotero 插件